C. Haferlach

T. Haferlach, N. Kröger, A. Zander, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

IDH1 Mutations Are Detected in 9.3% of All AML and Are Strongly Associated with Intermediate Risk Karyotype and Unfavourable Prognosis: a Study of 999 Patients

T. Haferlach, S. Schnittger, W. Kern, 2009 .

MYC rearranged B-cell neoplasms: Impact of genetics on classification.

T. Haferlach, W. Kern, A. Stengel, 2016, Cancer genetics.

The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Genes, chromosomes & cancer.

Landscape of TET2 mutations in acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Leukemia.

AML with CBFB–MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions

A. Kohlmann, T. Haferlach, S. Schnittger, 2010, Leukemia.

Monoclonal B‐cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early‐stage CLL

T. Haferlach, S. Schnittger, W. Kern, 2012, British journal of haematology.

“Somatic” and “pathogenic” - is the classification strategy applicable in times of large-scale sequencing?

T. Haferlach, W. Kern, Stephan Hutter, 2019, Haematologica.

EZH2 mutations and their association with PICALM‐MLLT10 positive acute leukaemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, British journal of haematology.

Eμ/miR-125b transgenic mice develop lethal B-cell malignancies

Y Enomoto, J Kitaura, K Hatakeyama, 2011, Leukemia.

Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgVH status and immunophenotyping

T. Haferlach, S. Schnittger, W. Kern, 2007, Leukemia.

Development and validation of a real-time quantification assay to detect and monitor BRAF V 600 E mutations in hairy cell leukemia

T. Haferlach, S. Schnittger, W. Kern, 2012 .

CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk

Shondra M. Pruett-Miller, M. Babu, Chunxu Qu, 2022, Nature Genetics.

Abstract 1514: Significance assessment of mutations in 944 MDS patients using publicly available variant databases and mutation impact prediction software

T. Haferlach, W. Kern, C. Haferlach, 2016 .

SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia

T. Haferlach, W. Kern, Stephan Hutter, 2021, Leukemia.

Correlation of flow cytometrically determined expression of ZAP‐70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia

T. Haferlach, S. Schnittger, W. Kern, 2009, Cytometry. Part B, Clinical cytometry.

The diverse landscape of fusion transcripts in 25 different hematological entities

T. Haferlach, W. Kern, Stephan Hutter, 2020, Leukemia and Lymphoma.

Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms

Masao Nagasaki, Satoru Miyano, Yuichi Shiraishi, 2012, Nature Genetics.

Identification of a specific immunophenotype associated with a consistent pattern of genetic mutations including SRFS2 and gene expression profile in MDS.

T. Haferlach, W. Kern, C. Haferlach, 2022, Cytometry. Part B, Clinical cytometry.

Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.

F. Solé, T. Haferlach, J. Maciejewski, 2020, Blood.

Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q

K. Döhner, M. Heuser, F. Thol, 2015, Leukemia.

Detection and characterization of homozygosity of mutated CALR by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high CALR mutation loads or with progressive disease

T. Haferlach, W. Kern, A. Stengel, 2018, Haematologica.

Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera

T. Haferlach, H. Slawik, S. Schnittger, 2009, Haematologica.

JAK2 seems to be a typical cooperating mutation in therapy-related t(8;21)/ AML1-ETO-positive AML

T. Haferlach, S. Schnittger, W. Kern, 2007, Leukemia.

The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers

T. Haferlach, S. Schnittger, W. Kern, 2007, Annals of Hematology.

JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases

T. Haferlach, S. Schnittger, W. Kern, 2007, Leukemia.

Comprehensive molecular characterization of myeloid malignancies with 9q deletion

T. Haferlach, W. Kern, A. Stengel, 2019, Leukemia & lymphoma.

Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients

T. Haferlach, S. Schnittger, W. Kern, 2015, Cytometry. Part B, Clinical cytometry.

Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact

T. Haferlach, S. Schnittger, W. Kern, 2014, British journal of haematology.

A comprehensive approach to the diagnosis of MDS after triage by morphology towards cytogenetics and other techniques

T. Haferlach, S. Schnittger, W. Kern, 2007 .

Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus

S. Bens, W. Klapper, R. Siebert, 2016, Molecular and Cellular Pediatrics.

Hematologist‐Level Classification of Mature B‐Cell Neoplasm Using Deep Learning on Multiparameter Flow Cytometry Data

T. Haferlach, Max Zhao, P. Krawitz, 2020, medRxiv.

Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy

C. Haferlach, H. Kolb, R. Schwerdtfeger, 2007, Leukemia & lymphoma.

A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98–NSD1 fusion gene

T. Haferlach, S. Schnittger, W. Kern, 2013, Leukemia.

Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.

Martin C. Müller, C. Haferlach, P. Erben, 2006, Haematologica.

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Leukemia.

An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome

J. Tchinda, S. Raimondi, N. Heerema, 2014, Leukemia.

Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia

C. Haferlach, B. Gruhn, A. Hochhaus, 2018, Leukemia.

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse.

T. Haferlach, W. Kern, C. Haferlach, 2018, Blood advances.

Somatic Mutations and Inborn Variants in Exon 12 of ASXL1 in Different Myeloid Neoplasms

H. Wichmann, N. Klopp, T. Illig, 2011 .

Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis

T. Haferlach, S. Schnittger, W. Kern, 2008, Leukemia.

Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.

C. Haferlach, A. Reiter, N. Cross, 2007, Haematologica.

SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.

S. Ogawa, A. Kohlmann, T. Haferlach, 2010, Blood.

Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups

J. Tchinda, D. Reinhardt, C. Haferlach, 2016, Cancer.

Application of precision medicine in clinical routine in haematology—Challenges and opportunities

S. Fröhling, L. Bullinger, T. Fioretos, 2022, Journal of internal medicine.

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis

T. Haferlach, W. Hofmann, S. Schnittger, 2016, Leukemia.

A novel recurrent AML1–ETO fusion: tight in vivo association with BCR–ABL1

M. Griesshammer, S. Schnittger, C. Haferlach, 2013, Leukemia.

Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.

T. Haferlach, C. Vetro, W. Kern, 2019, Cancer genetics.

FISH in der Diagnostik hämatologischer Neoplasien

C. Haferlach, U. Bacher, U. Bacher, 2008 .

Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop.

F. Solé, G. Mufti, J. Maciejewski, 2012, Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis.

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL

R. Siebert, T. Aittokallio, S. Mustjoki, 2019, Cancers.

Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2

T. Haferlach, W. Kern, C. Haferlach, 2018, Haematologica.

Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?

F. Solé, S. Jhanwar, L. Campbell, 2012, Leukemia research.

Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma.

T. Haferlach, S. Schnittger, W. Kern, 2013, Experimental hematology.

Frequency and prognostic impact of the aberrant CD8 expression in 5,523 patients with chronic lymphocytic leukemia

T. Haferlach, S. Schnittger, W. Kern, 2012, Cytometry. Part B, Clinical cytometry.

Enhancer hijacking drives oncogenic BCL11B expression in lineage ambiguous stem cell leukemia.

M. Loh, M. Relling, C. Pui, 2021, Cancer discovery.

Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genes

T. Haferlach, W. Hofmann, C. Haferlach, 2020, American journal of hematology.

Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia

E. Sabattini, B. Huntly, G. Martinelli, 2019, Cancers.

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

N. Schmitz, H. Heimpel, H. Döhner, 2015, Leukemia.

Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia

E. Campo, N. Villamor, J. Delgado, 2018, Haematologica.

TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype

M. Salido, S. Beà, T. Baumann, 2022, Cancers.

Diagnostic challenge of identifying cases with recurrent t(8;14)(q24.21;q32.2) Involving BCL11B in acute leukemias of ambiguous lineage: an analysis of eight patients

T. Haferlach, W. Kern, A. Stengel, 2021, Leukemia & lymphoma.

Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis

A. Kohlmann, T. Haferlach, S. Schnittger, 2010, Haematologica.

Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis

T. Haferlach, S. Schnittger, W. Kern, 2009, Haematologica.

Several lymphoma‐specific genetic events in parallel can be found in mature B‐cell neoplasms

T. Haferlach, S. Schnittger, W. Kern, 2011, Genes, chromosomes & cancer.

Artificial intelligence in hematological diagnostics: Game changer or gadget?

T. Haferlach, W. Kern, C. Haferlach, 2022, Blood reviews.

Dreams can come true: the first steps toward a peripheral blood screening test for the early detection of tumors have been taken.

T. Haferlach, C. Haferlach, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase

W. Hofmann, C. Haferlach, A. Reiter, 2013, Leukemia.

GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Leukemia.

Prognostic value of monosomal karyotype in comparison to complex aberrant karyotype in acute myeloid leukemia: a study on 824 cases with aberrant karyotype.

T. Haferlach, S. Schnittger, W. Kern, 2012, Blood.

Monitoring of minimal residual disease in acute myeloid leukemia

T. Haferlach, S. Schnittger, W. Kern, 2005, Cancer.

STAT3 mutations are highly specific for large granular lymphocytic leukemia

T. Haferlach, S. Schnittger, W. Kern, 2013, Leukemia.

Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B‐CLL) and its genetic characterization

T. Haferlach, S. Schnittger, W. Kern, 2014, British Journal of Haematology.

Multiparameter flow cytometry reveals myelodysplasia‐related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms

T. Haferlach, S. Schnittger, W. Kern, 2013, Cytometry. Part B, Clinical cytometry.

Flow Cytometric Findings Indicative of Myelodysplasia Differ Depending on the Karyotype

T. Haferlach, S. Schnittger, W. Kern, 2008 .

Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies

A. Kohlmann, T. Haferlach, S. Schnittger, 2010, Annals of Hematology.

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

Martin C. Müller, H. Einsele, J. Hasford, 2014, Haematologica.

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations

K. Stamatopoulos, C. Haferlach, A. Kater, 2022, HemaSphere.

The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML

T. Haferlach, S. Schnittger, W. Kern, 2011, Leukemia.

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

T. Haferlach, G. Garcia-Manero, J. Maciejewski, 2018, Blood.

Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q

L. Arenillas, F. Solé, T. Haferlach, 2022, EBioMedicine.

Landmark analysis of DNMT3A mutations in hematological malignancies

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Leukemia.

Older Age Is An Independent Risk Factor in AML

W. Hiddemann, T. Haferlach, K. Spiekermann, 2008 .

Mutations of TET2 and JAK2 but Not CBL Are Detectable in a High Portion of Patients with Refractory Anemia with Ring Sideroblasts and Thrombocytosis (RARS-T).

A. Kohlmann, T. Haferlach, S. Schnittger, 2009 .

C009 Identification of dysplastic features in patients with myelodysplastic syndromes by multiparameter flow cytometry and correlation with cytomorphology and cytogenetics

T. Haferlach, S. Schnittger, W. Kern, 2007 .

Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements

W. Hofmann, C. Haferlach, A. Chase, 2013, Haematologica.

Impact of 9q deletions on the classification of patients with acute myeloid leukemia

T. Haferlach, W. Kern, A. Stengel, 2019, Journal of Cancer Research and Clinical Oncology.

Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA

T. Haferlach, S. Schnittger, W. Kern, 2011, Haematologica.

Will a Peripheral Blood (PB) Sample Yield the Same Diagnostic and Prognostic Cytogenetic Data as the Concomitant Bone Marrow (BM) In Myelodysplasia? An International Study Comparing Cytogenetics and Interphase FISH Using Parallel PB and BM Samples

F. Solé, S. Jhanwar, L. Campbell, 2010 .

ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events

T. Haferlach, S. Schnittger, W. Kern, 2012, Genes, chromosomes & cancer.

Multiparameter Flow Cytometry Provides Independent Prognostic Information in Patients with Suspected Myelodysplastic Syndromes: A Study on 804 Patients.

T. Haferlach, S. Schnittger, W. Kern, 2016, Cytometry. Part B, Clinical cytometry.

RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome

T. Haferlach, W. Kern, A. Stengel, 2019, Leukemia & lymphoma.

RARS-T Patients Harbor SF3B1 Mutations In 90.2% and Can Be Characterized By Mutations In ASXL1 and Other Spliceosome Genes In Most Of The Remaining Cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2013 .

Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Leukemia.

Prognostic of Core Binding Factor (CBF) Acute Myeloid Leukemia With Complex Karyotype.

C. Haferlach, T. Cluzeau, N. Boissel, 2021, Clinical lymphoma, myeloma & leukemia.

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia

E. Thiel, W. Hiddemann, T. Haferlach, 2016, Leukemia.

Robustness of amplicon deep sequencing underlines its utility in clinical applications.

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, The Journal of molecular diagnostics : JMD.

Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia.

N. Schmitz, T. Haferlach, S. Schnittger, 2013, Leukemia research.

Analyses of 81 Chronic Myelomonocytic Leukemia (CMML) for EZH2, TET2, ASXL1, CBL, KRAS, NRAS, RUNX1, IDH1, IDH2, and NPM1 Revealed Mutations In 86.4% of All Patients with TET2 and EZH2 Being of High Prognostic Relevance

A. Kohlmann, T. Haferlach, S. Schnittger, 2010 .

A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2007, Cancer genetics and cytogenetics.

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

H. Einsele, J. Hasford, K. Spiekermann, 2012, Leukemia.

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML

T. Haferlach, S. Schnittger, W. Kern, 2010, Genes, chromosomes & cancer.

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Martin C. Müller, J. Hasford, A. Zander, 2010, Blood.

RQ‐PCR based WT1 expression in comparison to BCR‐ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib‐treated chronic myeloid leukaemia

T. Haferlach, S. Schnittger, W. Kern, 2009, British journal of haematology.

Impact of assay procedures on detection of MR4.5 status in chronic myeloid leukemia: Optimization of cDNA synthesis

T. Haferlach, W. Kern, C. Haferlach, 2019, International journal of laboratory hematology.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Imatinib-Era: Update on the Survival Outcome Following Allogeneic HSCT after Imatinib Failure; Results of the German CML Study IV

Martin C. Müller, J. Hasford, A. Zander, 2008 .

Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib

C. Haferlach, C. Peschel, J. Duyster, 2007, Bone Marrow Transplantation.

leukemia identifies heterogeneous secondary genomic alterations SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid

S. Ogawa, A. Kohlmann, T. Haferlach, 2011 .

Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox

C. Haferlach, J. Schlué, A. Giagounidis, 2016, Oncology Research and Treatment.

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)

C. Haferlach, R. Hehlmann, A. Fabarius, 2022, Leukemia.

A new case with rare e6a2 BCR–ABL fusion transcript developing two new resistance mutations during imatinib mesylate, which were replaced by T315I after subsequent dasatinib treatment

T. Haferlach, S. Schnittger, W. Kern, 2008, Leukemia.

Development of An Oligonucleotide Resequencing Array for Rapid Mutation Analysis in Acute Myeloid Leukemia with Normal Karyotype.

T. Haferlach, S. Schnittger, W. Kern, 2009 .

Cytogenetic methods in chronic lymphocytic leukemia.

C. Haferlach, U. Bacher, 2011, Methods in molecular biology.

Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML

T. Haferlach, B. Falini, G. Avvisati, 2021, Blood.

Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase

K. Döhner, T. Haferlach, J. Panse, 2017, Annals of Hematology.

Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B‐cell neoplasms

T. Haferlach, S. Schnittger, W. Kern, 2010, British journal of haematology.

Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis

Martin C. Müller, C. Haferlach, A. Reiter, 2010, Haematologica.

Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters

T. Haferlach, S. Schnittger, W. Kern, 2010, Genes, chromosomes & cancer.

Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2007, Cancer genetics and cytogenetics.

Short communication Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia

T. Haferlach, S. Schnittger, W. Kern, 2007 .

Minimal Residual Disease Assessed by NPM1 Mutation Specific RQ-PCR Is the Most Relevant Prognostic Parameter in NPM1-Mutated AML and Highly Useful to Guide Therapy

T. Haferlach, S. Schnittger, W. Kern, 2008 .

Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.

T. Haferlach, W. Hofmann, C. Haferlach, 2011, Blood.

Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group

W. Hiddemann, T. Haferlach, K. Spiekermann, 2011 .

Correlation of Mutation Patterns with Patient Age in 2656 Cases with 11 Different Hematological Malignancies

T. Haferlach, W. Kern, A. Stengel, 2020 .

A Novel Machine Learning Based in silico Pathogenicity Predictor for Missense Variants in a Hematological Setting

T. Haferlach, W. Kern, C. Haferlach, 2019, Blood.

Molecular determinants of prognosis in acute myeloid leukemia (AML) with normal karyotype

C. Haferlach, U. Bacher, 2009, Leukemia & lymphoma.

To the editor: Elevated ﬁbrinogen (cid:1) (cid:2) ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome

C. Haferlach, 2009 .

SRSF2 is Mutated in 47.2% (77/163) of Chronic Myelomonocytic Leukemia (CMML) and Prognostically Favorable in Cases with Concomitant RUNX1 mutations

S. Ogawa, A. Kohlmann, T. Haferlach, 2011 .

High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Leukemia.

Case Report: Personalized Therapeutical Approaches with Lenalidomide in Del(5q): A Case Series

C. Haferlach, U. Platzbecker, A. Kubasch, 2022, Frontiers in Oncology.

The role of different genetic subtypes of CEBPA mutated AML

C Haferlach, A Kohlmann, T Haferlach, 2014, Leukemia.

CEBPA double‐mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, British journal of haematology.

Sole Trisomy 8 in AML: Concomitant Molecular Markers, Stability of Genetic Patterns and Impact On Outcome.

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML

Martin C. Müller, J. Hasford, T. Brümmendorf, 2015, Annals of Hematology.

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Haematologica.

Chronic Myeloproliferative Disorders

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myeloproliferative / myelodysplastic disorders : an analysis of 636 cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

A Specific Gene Expression Signature Affecting the Beta-Catenin and Notch Signaling Pathways and the Downregulation of MALAT1 Prove Acute Myeloid Leukemia with Limited Differentiation (AML-LD) as a Distinct Entity with NPM1 Mutation.

A. Kohlmann, T. Haferlach, S. Schnittger, 2009 .

How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing

T. Haferlach, W. Kern, J. Müller, 2022, Leukemia.

Recurrent Mutations of Multiple Components of Cohesin Complex in Myeloid Neoplasms

S. Ishikawa, H. Aburatani, K. Shirahige, 2012 .

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Haematologica.

Aberrations identified by genomic arrays in normal karyotype CMML can be detected in 40% of patients, but do not add prognostic information to molecular mutations

T. Haferlach, C. Vetro, W. Kern, 2016, Leukemia.

An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Leukemia.

Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation

T. Haferlach, W. Kern, A. Stengel, 2022, Molecular Biology Reports.

Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2010, Cancer genetics and cytogenetics.

Short communication Detection of a t(4;14)(p16;q32) in two cases of lymphoma showing both the immunophenotype of chronic lymphocytic leukemia

T. Haferlach, S. Schnittger, W. Kern, 2010 .

The diverse landscape of fusion transcripts in 25 different hematological entities

T. Haferlach, W. Kern, A. Stengel, 2020, Leukemia & lymphoma.

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis

T. Haferlach, W. Kern, C. Haferlach, 2022, Leukemia.

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase

T. Haferlach, W. Kern, C. Haferlach, 2022, Leukemia.

Molecular landscape of acute promyelocytic leukemia at diagnosis and relapse

T. Haferlach, W. Kern, C. Haferlach, 2017, Haematologica.

Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.

L. Pasqualucci, L. Farinelli, R. Rabadán, 2011, Blood.

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics

T. Haferlach, W. Kern, A. Stengel, 2022, Leukemia.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

P. Campbell, M. Cazzola, D. Neuberg, 2019, Leukemia.

Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q

K. Döhner, M. Heuser, F. Thol, 2021, American journal of hematology.

CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Haematologica.

RUNX1 Mutations Can Be Found in 34% of De Novo AML with Normal Karyotype or Single Chromosomal Imbalances and Are Associated with Good Prognosis but Turn to Unfavourable Outcome If Further Cytogenetic or Molecular Mutations Are Acquired

T. Haferlach, S. Schnittger, W. Kern, 2008 .

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Martin C. Müller, H. Heimpel, H. Einsele, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of multiparameter flow cytometry for disease monitoring in AML.

Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, 2010, Best practice & research. Clinical haematology.

The European LeukemiaNet: achievements and perspectives

P. Schrotz-King, H. Döhner, H. Einsele, 2011, Haematologica.

The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops

T. Haferlach, S. Gröschel, L. Smeenk, 2021, Nature Communications.

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

Martin C. Müller, H. Einsele, J. Hasford, 2011, Blood.

Subtype-specific patterns of molecular mutations in acute myeloid leukemia

T. Haferlach, S. Schnittger, W. Kern, 2017, Leukemia.

TP53 Mutations in Acute Myeloid Leukemia

T. Haferlach, S. Schnittger, C. Haferlach, 2015 .

Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.

T. Haferlach, S. Schnittger, W. Kern, 2012, Leukemia research.

Subclones with the t(9;22)/BCR‐ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations

T. Haferlach, S. Schnittger, W. Kern, 2011, British journal of haematology.

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis.

T. Haferlach, J. Sundermann, S. Schnittger, 2011, Blood.

Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2007, Blood.

SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis

T. Haferlach, S. Schnittger, W. Kern, 2013, Leukemia.

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

T. Brümmendorf, K. Spiekermann, M. Pfreundschuh, 2017, Leukemia.

Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype

T. Haferlach, S. Schnittger, W. Kern, 2013, Leukemia.

Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

T. Haferlach, B. Falini, S. Schnittger, 2009, Blood.

BRAF mutations in hairy-cell leukemia.

S. Pileri, L. Pasqualucci, L. Farinelli, 2011, The New England journal of medicine.

SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML).

S. Ogawa, A. Kohlmann, T. Haferlach, 2012, Blood.

The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?

T. Haferlach, W. Kern, C. Haferlach, 2020, Cancer genetics.

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.

A. Trumpp, H. Blum, D. Nowak, 2016, Blood.

Analysis for loss of heterozygosity on chromosome arm 13q by STR analysis or SNP sequencing can replace analysis of FLT3‐ITD to detect patients with prognostically adverse AML

T. Haferlach, S. Schnittger, W. Kern, 2014, Genes, chromosomes & cancer.

Discussion of the applicability of microarrays: profiling of leukemias.

A. Kohlmann, T. Haferlach, C. Haferlach, 2009, Methods in molecular biology.

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

T. Haferlach, S. Schnittger, W. Kern, 2008, Blood.

Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients

J. Hernández-Rivas, A. Kohlmann, T. Haferlach, 2013, Leukemia.

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification.

T. Haferlach, M. Heymans, W. Kern, 2021, Blood advances.

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML

T. Haferlach, W. Kern, C. Haferlach, 2021, Cancers.

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

T. Haferlach, S. Schnittger, W. Kern, 2010, Blood.

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

T. Haferlach, S. Schnittger, W. Kern, 2010, Blood.

Involvement of the MLL gene in adult T‐lymphoblastic leukemia

B. Timmermann, R. Marschalek, C. Haferlach, 2012, Genes, chromosomes & cancer.

Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in >80% of patients with TET2 and EZH2 being of high prognostic relevance

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Leukemia.

Accumulation of adverse prognostic markers worsens prognosis in chronic lymphocytic leukaemia

T. Haferlach, S. Schnittger, W. Kern, 2015, British journal of haematology.

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations

T. Haferlach, W. Kern, C. Haferlach, 2019, HemaSphere.

Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes

T. Haferlach, W. Kern, C. Haferlach, 2017, Haematologica.

SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations

C Haferlach, T Haferlach, T. Haferlach, 2013, Leukemia.

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases

T. Haferlach, W. Kern, A. Stengel, 2017, Leukemia.

Gain of chromosome 21 or amplification of chromosome arm 21q is one mechanism for increased ERG expression in acute myeloid leukemia

T. Haferlach, S. Schnittger, W. Kern, 2016, Genes, chromosomes & cancer.

The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype

T. Haferlach, S. Schnittger, W. Kern, 2009, Leukemia.

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy

Martin C. Müller, W. Hofmann, C. Haferlach, 2015, PloS one.

Detection of centrosome aberrations in disease‐unrelated cells from patients with tumor treated with tyrosine kinase inhibitors

W. Hofmann, P. Duesberg, C. Haferlach, 2010, European journal of haematology.

Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib

A. Krämer, P. Duesberg, C. Haferlach, 2008, Haematologica.

MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences

M. Severgnini, L. Bullinger, G. Martinelli, 2018, Leukemia.

Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

P. Abrisqueta, J. Delgado, K. Stamatopoulos, 2019, Blood.

Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedure

C Haferlach, M Dugas, A Kohlmann, 2011, Leukemia.

Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype

Carl W. Miller, S. Ogawa, T. Haferlach, 2009, Haematologica.

Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo

A. Kohlmann, L. Klein-Hitpass, S. Schnittger, 2013, Cancer cell.

Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA

R. Schlenk, A. Ganser, K. Götze, 2017, Journal of Medical Genetics.

Frequency and Prognostic Impact of CEBPA Proximal, Distal and Core Promoter Methylation in Normal Karyotype AML: A Study on 623 Cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, PloS one.

Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.

J. Maciejewski, C. Haferlach, R. Tiu, 2008, Cancer genetics and cytogenetics.

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma

N. Schmitz, R. Siebert, H. Döhner, 2007, Leukemia.

Leukemia diagnosis: today and tomorrow

T. Haferlach, M. Béné, C. Haferlach, 2015, European journal of haematology.

A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2007, Haematologica.

Diagnostic pathways in acute leukemias: a proposal for a multimodal approach

T. Haferlach, S. Schnittger, W. Kern, 2007, Annals of Hematology.

Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1

T. Haferlach, S. Schnittger, W. Kern, 2013, Annals of Hematology.

Translocation t(8;9)(p12;q33) detected in cALL: A case report

C. Haferlach, M. Zenger, 2012 .

The new provisional WHO entity ‘RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia

T. Haferlach, W. Kern, S. Eckstein, 2016, Leukemia.

BRCC3 mutations in myeloid neoplasms

H. Aburatani, S. Miyano, Y. Shiraishi, 2015, Haematologica.

Diversity of the juxtamembrane and TKD1 mutations (Exons 13–15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data

T. Haferlach, S. Schnittger, W. Kern, 2012, Genes, chromosomes & cancer.

Clinical application of whole transcriptome sequencing for the classification of patients with acute lymphoblastic leukemia

T. Haferlach, W. Kern, A. Stengel, 2021, BMC cancer.

Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Genes, chromosomes & cancer.

Another piece of the AML puzzle.

T. Haferlach, C. Haferlach, 2013, Blood.

SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3

Martin C. Müller, S. Ogawa, A. Kohlmann, 2012, Genes, chromosomes & cancer.

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

C Haferlach, H Aburatani, S Miyano, 2013, Leukemia.

Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Haematologica.

TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, British journal of haematology.

Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis

T. Haferlach, S. Schnittger, W. Kern, 2016, Leukemia.

Whole genome sequencing demonstrates substantial pathophysiological differences of MYC rearrangements in patients with plasma cell myeloma and B-cell lymphoma

T. Haferlach, W. Kern, A. Stengel, 2021, Leukemia & lymphoma.

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study

S. Schnittger, C. Haferlach, A. Reiter, 2008, British journal of haematology.

Molecular patterns in cytopenia patients with or without evidence of myeloid neoplasm—a comparison of 756 cases

T. Haferlach, W. Kern, C. Haferlach, 2018, Leukemia.

Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia

T. Haferlach, W. Kern, C. Haferlach, 2016, Haematologica.

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells

T. Haferlach, S. Schnittger, W. Kern, 2011, Haematologica.

Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.

Stefan W Krause, Alois Gratwohl, Claudia Haferlach, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrated analysis of copy number alterations and gene expression: a bivariate assessment of equally directed abnormalities

Martin Schäfer, Martin Dugas, Holger Schwender, 2009, Bioinform..

Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies

T. Haferlach, W. Kern, A. Stengel, 2021, Blood advances.

Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.

S. Miyano, Y. Shiraishi, K. Chiba, 2017, Blood.

Impact of genetic alterations in stem-cell transplantation for myelodysplasia and secondary acute myeloid leukemia Short title: Genetic alterations in myelodysplasia with HCT

S. Miyano, Y. Shiraishi, K. Chiba, 2017 .

Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma

A. Rosenwald, A. Saliba, H. Einsele, 2021, Nature Medicine.

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).

Paola Fazi, Marco Vignetti, Hans-Ulrich Klein, 2010, Blood.

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

A. Kohlmann, T. Haferlach, M. Vignetti, 2009, Blood.

Identification of prognostic parameters in CLL with no abnormalities detected by chromosome banding and FISH analyses

T. Haferlach, C. Vetro, W. Kern, 2018, British journal of haematology.

Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.

S. Miyano, Y. Shiraishi, K. Chiba, 2020, Blood advances.

Interactive diagnostics in the indication to allogeneic SCT in AML

T. Haferlach, S. Schnittger, W. Kern, 2009, Bone Marrow Transplantation.

Prognosis of MECOM (EVI1)-rearranged MDS and AML patients rather depends on accompanying molecular mutations than on blast count

T. Haferlach, W. Kern, A. Stengel, 2020, Leukemia & lymphoma.

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Blood Cancer Journal.

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

C. Steidl, L. Arenillas, F. Solé, 2011, Leukemia.

The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors

W. Hiddemann, S. Schnittger, C. Haferlach, 2007, Leukemia.

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV

J. Hasford, T. Brümmendorf, K. Spiekermann, 2018, Haematologica.

Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.

A. Trumpp, A. Kohlmann, S. Raffel, 2014, Cell stem cell.

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML

T. Haferlach, J. Sundermann, S. Schnittger, 2010, Leukemia.

Categorizing Molecular Mutations in MDS and AML

T. Haferlach, W. Kern, C. Haferlach, 2015 .

Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia

T. Haferlach, S. Schnittger, W. Kern, 2011, Leukemia.

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Leukemia.

Complex Landscape of Alternative Splicing in Myeloid Neoplasms

T. Haferlach, J. Maciejewski, W. Kern, 2020, Leukemia.

The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations.

B. Johansson, A. Hagemeijer, M. Slovak, 2010, Human molecular genetics.

SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Leukemia.

Donor-cell leukemia with novel genetic features 2 years after sex-mismatched T cell-depleted haploidentical stem cell transplantation

H. Einsele, C. Haferlach, S. Mielke, 2020, Annals of Hematology.

Application of an NGS‐based 28‐gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera

T. Haferlach, W. Kern, C. Haferlach, 2016, British journal of haematology.

Rare CBFB-MYH11 fusion transcripts in AML with inv(16)/t(16;16) are associated with therapy-related AML M4eo, atypical cytomorphology, atypical immunophenotype, atypical additional chromosomal rearrangements and low white blood cell count: a study on 162 patients

T. Haferlach, S. Schnittger, W. Kern, 2007, Leukemia.

W. Hiddemann, T. Haferlach, K. Spiekermann, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atypical mRNA fusions in PML‐RARA positive, RARA‐PML negative acute promyelocytic leukemia

S. Schnittger, C. Haferlach, A. Reiter, 2010, Genes, chromosomes & cancer.

t(3;7)(q26;q21) as a secondary abnormality in MDS RAEB-2

C. Haferlach, L. Reindl, 2011 .

Atlas of Genetics and Cytogenetics in Oncology and Haematology

C. Haferlach, L. Reindl, 2010 .

Case Report Section Paper co-edited with the European LeukemiaNet

C. Haferlach, 2010 .

CASE REPORTS in HAEMATOLOGY (Paper co-edited with the European LeukemiaNet)

C. Haferlach, L. Reindl, 2010 .

Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML

T. Haferlach, S. Schnittger, C. Haferlach, 2007, Leukemia & lymphoma.

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA

Kahn Rhrissorrakrai, Torsten Haferlach, Wolfgang Kern, 2019, PLoS Comput. Biol..

A novel hierarchical prognostic model of AML solely based on molecular mutations.

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Blood.

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group

W. Hiddemann, T. Haferlach, K. Spiekermann, 2012, Annals of Hematology.

Aberrant somatic hypermutation of CCND1 generates non-coding drivers of mantle cell lymphomagenesis

T. Haferlach, W. Kern, C. Haferlach, 2022, Cancer gene therapy.

TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes

M. Minden, T. Haferlach, J. Maciejewski, 2021, Blood advances.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL).

U. Jaeger, M. Mayerhoefer, T. Kadia, 2019, Blood.

Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes

W. Hiddemann, T. Haferlach, K. Spiekermann, 2010, The Lancet.

The kinetics of relapse in DEK‐NUP214‐positive acute myeloid leukemia patients

T. Haferlach, E. Macintyre, S. Schnittger, 2015, European journal of haematology.

Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL.

E. Campo, A. Navarro, K. Stamatopoulos, 2020, Blood.

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.

M. Cazzola, T. Haferlach, C. Haferlach, 2016, Blood.

Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations

T. Haferlach, W. Kern, C. Haferlach, 2016, Leukemia.

Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia

T. Haferlach, S. Schnittger, W. Kern, 2016, British journal of haematology.

Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Genes, chromosomes & cancer.

Genetic characterization of T‐PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker

T. Haferlach, S. Schnittger, W. Kern, 2016, Genes, chromosomes & cancer.

IDH Mutations Can Be Detected In 28.7% of All Normal Karyotype AML and Have Unfavourable Impact on the NPM1+/FLT3-ITD- Genotype

T. Haferlach, S. Schnittger, W. Kern, 2010 .

Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome

Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, 2014, Genes, chromosomes & cancer.

Diagnostic and Prognostic Utility Of a 26-Gene Panel For Deep-Sequencing Mutation Analysis In Myeloid Malignancies

T. Haferlach, S. Schnittger, W. Kern, 2013 .

Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic markers stepwise worsens the prognosis

T. Haferlach, W. Kern, C. Haferlach, 2016, Blood Cancer Journal.

Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients

F. Bosch, S. Beà, T. Baumann, 2021, Haematologica.

Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia

T. Haferlach, W. Kern, C. Haferlach, 2017, Leukemia.

How artificial intelligence might disrupt diagnostics in hematology in the near future

T. Haferlach, W. Kern, C. Haferlach, 2021, Oncogene.

Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML.

T. Haferlach, N. Kröger, S. Schnittger, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome

T. Haferlach, S. Schnittger, W. Kern, 2014, Leukemia.

NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia

S. Pileri, T. Haferlach, B. Falini, 2008, Haematologica.

Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT

C. Haferlach, C. Schulte, R. Trenschel, 2009, Bone Marrow Transplantation.

Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines

W. Hiddemann, K. Spiekermann, D. Nowak, 2018, European journal of haematology.

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia

Christoph Schmid, Torsten Haferlach, Wolfgang Kern, 2016, Haematologica.

AML with gain of chromosome 8 as the sole chromosomal abnormality (+8sole) is associated with a specific molecular mutation pattern including ASXL1 mutations in 46.8% of the patients.

T. Haferlach, S. Schnittger, W. Kern, 2015, Leukemia research.

Molecular subtypes of NPM 1 mutations have different clinical profiles , specific patterns of accompanying molecular mutations and varying outcome in intermediate risk acute myeloid leukemia

N. Schmitz, S. Schnittger, W. Kern, 2015 .

Quantification of rare NPM1 mutation subtypes by digital PCR

T. Haferlach, S. Schnittger, W. Kern, 2014, British journal of haematology.

Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS.

T. Haferlach, W. Kern, A. Stengel, 2020, Blood advances.

Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia

T. Haferlach, C. Vetro, W. Kern, 2019, Leukemia.

Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML

T. Haferlach, W. Kern, A. Stengel, 2018, Leukemia.

WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups

T. Haferlach, S. Schnittger, W. Kern, 2014, Leukemia.

Male predominance in AML is associated with specific preleukemic mutations

C. Haferlach, L. Shlush, M. Meggendorfer, 2020, Leukemia.

European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms

E. van den Berg, C. Haferlach, Z. Zemanová, 2019, Leukemia.

Single and double hit events in genes encoding for immune targets before and after T cell engaging antibody therapy in MM.

A. Rosenwald, H. Einsele, N. Bolli, 2021, Blood advances.

Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration

T. Haferlach, W. Kern, C. Haferlach, 2021, Leukemia.

Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia‐associated myeloproliferative neoplasms

W. Hofmann, S. Schnittger, C. Haferlach, 2015, Genes, chromosomes & cancer.

Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations

T. Haferlach, W. Kern, A. Stengel, 2019, Genes, chromosomes & cancer.

Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions

S. Ogawa, T. Haferlach, S. Schnittger, 2016, Leukemia.

Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes

T. Haferlach, G. Garcia-Manero, J. Maciejewski, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

T. Haferlach, S. Schnittger, W. Kern, 2008, Leukemia.

Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients

T. Haferlach, S. Schnittger, W. Kern, 2012, Cytometry. Part B, Clinical cytometry.

Newly acquired kiwi fruit allergy after bone marrow transplantation from a kiwi‐allergic donor

J. Ring, T. Biedermann, C. Haferlach, 2016, Journal of the European Academy of Dermatology and Venereology.

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence

T. Haferlach, J. Maciejewski, Y. Nagata, 2019, Blood.

CML Patients with Resistance to Tyrosine Kinase Inhibitors and without BCR-ABL1 Resistance Mutation Frequently Carry Other Gene Mutations

T. Haferlach, S. Schnittger, W. Kern, 2014 .

Randomized Comparison of Imatinib 400 Mg Vs. Imatinib + IFN Vs. Imatinib + AraC Vs. Imatinib after IFN Vs. Imatinib 800 Mg: Optimized Treatment and Survival. Designed First Interim Analysis of the German CML Study IV

Martin C. Müller, H. Heimpel, J. Hasford, 2008 .

Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia

C Haferlach, W Hiddemann, T Haferlach, 2016, Leukemia.

Correlation of cytomorphology, immunophenotyping, and interphase fluorescence in situ hybridization in 381 patients with monoclonal gammopathy of undetermined significance and 301 patients with plasma cell myeloma.

T. Haferlach, S. Schnittger, W. Kern, 2010, Cancer genetics and cytogenetics.

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Haematologica.

Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics

T. Haferlach, S. Schnittger, W. Kern, 2013, Haematologica.

Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome

T. Haferlach, S. Schnittger, W. Kern, 2010, Cancer.

Clinical Utility of Multiparameter Flow Cytometry in the Diagnosis of 1013 Patients with Suspected Myelodysplastic Syndrome: Correlation to Cytomorphology, Cytogenetic, and Clinical Data.

T. Haferlach, S. Schnittger, W. Kern, 2009 .

BCR‐ABL1‐positive and JAK2 V617F‐positive clones in 23 patients with both aberrations reveal biologic and clinical importance

T. Haferlach, S. Schnittger, W. Kern, 2017, British journal of haematology.

Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia

T. Haferlach, S. Schnittger, W. Kern, 2014, Haematologica.

Detection of Three Different MPLW515 Mutations in 10.1% of All JAK2 V617 Unmutated ET and 9.3% of All JAK2 V617F Unmutated OMF: A Study of 387 Patients.

T. Haferlach, S. Schnittger, W. Kern, 2007 .

Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category

T. Haferlach, S. Schnittger, W. Kern, 2009, Annals of Hematology.

Acute monoblastic/monocytic leukemia and chronic myelomonocytic leukemia share common immunophenotypic features but differ in the extent of aberrantly expressed antigens and amount of granulocytic cells

T. Haferlach, S. Schnittger, W. Kern, 2011, Leukemia & lymphoma.

Early allo-SCT for AML with a complex aberrant karyotype—results from a prospective pilot study

W. Hiddemann, K. Spiekermann, C. Haferlach, 2012, Bone Marrow Transplantation.

Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all demonstrating more than 50 % of bone marrow erythropoietic cells

T. Haferlach, S. Schnittger, W. Kern, 2011 .

Combined Impact of Aberrant Immunophenotypes, Somatic Mutations and Cytogenetic Aberrations on the Probability of Developing Myelodysplasia in Patients with Cytopenias of Undetermined Significance

T. Haferlach, W. Kern, C. Haferlach, 2018, Blood.

The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes

T. Haferlach, S. Schnittger, W. Kern, 2009, Cancer.

Flow cytometric identification of acute myeloid leukemia with limited differentiation and NPM1 type A mutation: a new biologically defined entity

T. Haferlach, S. Schnittger, W. Kern, 2009, Leukemia.

A geno-clinical decision model for the diagnosis of myelodysplastic syndromes

T. Haferlach, J. Maciejewski, B. Jha, 2021, Blood Advances.

Evaluation Of Different NPM1 Mutations In AML Patients According To Clinical, Cytogenetic and Molecular Features and Impact On Outcome

A. Kohlmann, T. Haferlach, S. Schnittger, 2013 .

Detailed molecular analysis and evaluation of prognosis in cases with high grade B‐cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements

T. Haferlach, W. Kern, A. Stengel, 2018, British journal of haematology.

Insight into the molecular pathogenesis of myeloid malignancies

T. Haferlach, S. Schnittger, W. Kern, 2007, Current opinion in hematology.

Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study

K. Stamatopoulos, R. Rosenquist, C. Haferlach, 2020, Haematologica.

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

N. Schmitz, N. Klopp, T. Illig, 2013, Leukemia.

Gene expression profiling for the diagnosis of acute leukaemia

A. Kohlmann, T. Haferlach, S. Schnittger, 2006, British Journal of Cancer.

Deep Learning Algorithms Support Distinction of PV, PMF, and ET Based on Clinical and Genetic Markers

T. Haferlach, W. Kern, C. Haferlach, 2017 .

9 or trisomy 9

C. Haferlach, U. Bacher, 2011 .

European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms: reponse to the comments from the Francophone Group of Hematological Cytogenetics (GFCH)

E. van den Berg, C. Haferlach, Z. Zemanová, 2020, Leukemia.

A 13-Gene Panel Targeted To Investigate CLL By Next-Generation Amplicon Deep-Sequencing Can Be Successfully Implemented In Routine Diagnostics

A. Kohlmann, T. Haferlach, S. Schnittger, 2013 .

Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma

C. Haferlach, H. Serve, Sebastian E. Koschade, 2019, Annals of Hematology.

The role of the RAS pathway in iAMP21-ALL

A. Kohlmann, T. Haferlach, B. Keavney, 2016, Leukemia.

Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases.

T. Haferlach, S. Schnittger, C. Haferlach, 2007, Cancer genetics and cytogenetics.

Short communication Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases

T. Haferlach, S. Schnittger, C. Haferlach, 2007 .

MDS subclassification—do we still have to count blasts?

T. Haferlach, W. Kern, C. Haferlach, 2022, Leukemia.

MANGANESE deficiency.

E. Zackai, G. Reifenberger, T. Dierks, 2022, Journal of the American Veterinary Medical Association.

AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features

A. Kohlmann, T. Haferlach, S. Schnittger, 2009, Leukemia.

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients

T. Haferlach, W. Kern, C. Haferlach, 2018, Leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2010, Leukemia.

Molecular diagnostics in acute leukemias

T. Haferlach, S. Schnittger, C. Haferlach, 2009, Clinical chemistry and laboratory medicine.

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG

W. Hiddemann, T. Haferlach, K. Spiekermann, 2009, Leukemia.

Inverted duplication dup(1)(q32q21) as sole aberration in lymphoid and myeloid malignancies.

T. Haferlach, S. Schnittger, W. Kern, 2009, Cancer genetics and cytogenetics.

The gene expression classifier ALLCatchR identifies B-precursor ALL subtypes and underlying developmental trajectories across age

C. Kaleta, M. Schrappe, J. Kässens, 2023, bioRxiv.

The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia

J. Cigudosa, J. Fitzgibbon, M. Calasanz, 2017, Leukemia.

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.

Samuel W. Brady, C. Pui, T. Haferlach, 2022, Blood.

Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.

Martin C. Müller, H. Heimpel, J. Hasford, 2009 .

Molecularly Defined Clonal Evolution in Patients with Chronic Myeloid Leukemia Independent of the BCR-ABL Status

T. Haferlach, S. Schnittger, C. Haferlach, 2014 .

MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations

T. Haferlach, W. Kern, A. Stengel, 2016, Leukemia.

The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations

T. Haferlach, W. Kern, A. Stengel, 2016, Genes, chromosomes & cancer.

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes

W. Tapper, W. Hofmann, C. Haferlach, 2015, Annals of Hematology.

Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia

T. Haferlach, W. Kern, C. Haferlach, 2017, Haematologica.

Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase

J. Hasford, S. Schnittger, C. Haferlach, 2014, Journal of Cancer Research and Clinical Oncology.

Machine Learning Integrates Genomic Signatures for Subclassification Beyond Primary and Secondary Acute Myeloid Leukemia.

Jacob G. Scott, T. Haferlach, H. Kantarjian, 2021, Blood.

Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV

Martin C. Müller, H. Heimpel, H. Einsele, 2012 .

Detection of ABL1 kinase domain mutations in therapy-naïve BCR-ABL1-positive acute lymphoblastic leukemia

T. Haferlach, W. Kern, C. Haferlach, 2021, Haematologica.

Presentation and Diagnosis: Novel Molecular Markers and their Role in the Prognosis and Therapy of Acute Myeloid Leukemia

T. Haferlach, S. Schnittger, W. Kern, 2011 .

Gene expression analyses in acute myeloid leukaemia (AML): current status and perspectives

A. Kohlmann, T. Haferlach, S. Schnittger, 2008 .

Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN

A. Kohlmann, T. Haferlach, S. Schnittger, 2016, Leukemia.

The Potential of Molecular Genetic Analysis for Diagnostic and Prognostic Decision Making in Clonal Cytopenia of Undetermined Significance (CCUS) and MDS - a Study on 576 Patients

T. Haferlach, W. Kern, A. Stengel, 2020 .

Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement

M. Loh, V. V. D. van der Velden, Y. Bertrand, 2022, Haematologica.

Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS

T. Haferlach, W. Kern, A. Stengel, 2022, Blood.

Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis

W. Hofmann, C. Haferlach, K. Sotlar, 2018, Genes, chromosomes & cancer.

The Link between Cytogenetics/Genomics and Imaging Patterns of Relapse and Progression in Patients with Relapsed/Refractory Multiple Myeloma: A Pilot Study Utilizing 18F-FDG PET/CT

H. Einsele, A. Buck, C. Haferlach, 2020, Cancers.

AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes

T. Haferlach, C. Haferlach, K. Wimmer, 2009, Genes, chromosomes & cancer.

Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies

T. Haferlach, W. Kern, U. Martens, 2023, Leukemia.

Molecular Classification of AML-MRC Reveals a Distinct Profile and Identifies MRC-like Patients with Poor Overall Survival

T. Haferlach, W. Kern, A. Stengel, 2019, Blood.

In AML Secondary to MDS NPM1 Mutations Are Late Events, Less Frequent, and Associated with a Different Pattern of Molecular Mutations Than in De Novo AML

T. Haferlach, S. Schnittger, W. Kern, 2014 .

Multilineage dysplasia does not influence prognosis in CEBPA-mutated AML, supporting the WHO proposal to classify these patients as a unique entity.

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Blood.

Comprehensive analysis of the genetic landscape of 21 cases with blastic plasmacytoid dendritic cell neoplasm by whole genome and whole transcriptome sequencing

T. Haferlach, W. Kern, A. Stengel, 2021, Leukemia & lymphoma.

AML classification in the year 2023: How to avoid a Babylonian confusion of languages

T. Haferlach, W. Kern, C. Haferlach, 2023, Leukemia.

Evaluation of IDH1G105 polymorphism as prognostic marker in intermediate-risk AML

A. Peters, T. Haferlach, S. Schnittger, 2015, Annals of Hematology.

Amplification of EVI1 on cytogenetically cryptic double minutes as new mechanism for increased expression of EVI1.

T. Haferlach, S. Schnittger, W. Kern, 2014, Cancer genetics.

Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Genes, chromosomes & cancer.

Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).

S. Mercadal, F. Solé, M. Tormo, 2021, Leukemia research.

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

T. Brümmendorf, M. Baccarani, A. Gratwohl, 2019, Blood.

Robustness of comprehensive DNA- and RNA-based assays at diagnosis of acute myeloid leukemia using blood and bone marrow stored on filter cards

T. Haferlach, W. Kern, A. Stengel, 2016, Leukemia.

Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis

L. Arenillas, M. Cazzola, M. Rozman, 2012, Haematologica.

Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms

S. Miyano, T. Naoe, Y. Shiraishi, 2016, Leukemia.

Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion.

Sarah H. Johnson, J. Smadbeck, P. Blackburn, 2019, Cancer genetics.

Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia.

C. Haferlach, A. Chase, A. Reiter, 2007, Blood.

T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations

K. Stamatopoulos, R. Rosenquist, C. Haferlach, 2023, Frontiers in Oncology.

Gene expression profiling in acute myeloid leukaemia (AML).

A. Kohlmann, T. Haferlach, C. Haferlach, 2009, Best practice & research. Clinical haematology.

A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.

T. Haferlach, S. Schnittger, W. Kern, 2011, Experimental hematology.

Single Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.

A. Rosenwald, H. Einsele, N. Bolli, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

A. Kohlmann, T. Haferlach, S. Schnittger, 2015, Haematologica.

The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers

T. Haferlach, W. Kern, C. Haferlach, 2015, Leukemia.

Genes break barrier between MDS and AML.

C. Haferlach, 2015, Blood.

Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms

S. Miyano, Y. Shiraishi, S. Ogawa, 2021, Blood.

Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients

T. Haferlach, W. Kern, A. Stengel, 2019, Haematologica.

Evidence of clonality in cases of hypereosinophilia of undetermined significance

T. Haferlach, C. Vetro, W. Kern, 2019, Leukemia & lymphoma.

Ultra-Deep Next-Generation Sequencing Detects RUNX1 Mutations with Unprecedented Sensitivity and Allows to Monitor Minimal Residual Disease In 116 Samples From MDS and AML Patients

A. Kohlmann, T. Haferlach, S. Schnittger, 2010 .

ASXL1 exon 12 Mutations Are Frequent in AML with Intermediate Risk Karyotype and Are Independently Associated with An Extremely Poor Outcome

A. Kohlmann, T. Haferlach, S. Schnittger, 2011 .

IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies

T. Haferlach, B. Falini, W. Kern, 2018, Leukemia.

Additional Mutations in SRSF2, ASXL1 and/or RUNX1 Identify a High Risk Group of Patients with KIT D816V+ Advanced Systemic Mastocytosis

T. Haferlach, W. Hofmann, S. Schnittger, 2015 .

Three Steps to the Diagnosis of Adult Ph-like ALL

T. Haferlach, S. Schnittger, W. Kern, 2015 .

PF532 INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES

H. Aburatani, S. Miyano, Y. Shiraishi, 2019, HemaSphere.

A robust molecular pattern for myelodysplastic syndromes in two independent cohorts investigated by next‐generation sequencing can be revealed by comparative bioinformatic analyses

S. Ogawa, A. Kohlmann, T. Haferlach, 2014, British journal of haematology.

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

T. Haferlach, S. Schnittger, W. Kern, 2010, Blood.

Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?

T. Haferlach, K. Götze, W. Kern, 2023, Leukemia.

Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts

T. Haferlach, W. Kern, C. Haferlach, 2022, Leukemia.

Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms

T. Haferlach, J. Sundermann, S. Schnittger, 2011, Leukemia.

DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern

T. Haferlach, W. Kern, C. Haferlach, 2019, Leukemia.

Patients with therapy-related myelodysplastic syndromes and acute myeloid leukemia share genetic features but can be separated by blast counts and cytogenetic risk profiles into prognostically relevant subgroups

T. Haferlach, S. Schnittger, W. Kern, 2013, Leukemia & lymphoma.

Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia

T. Haferlach, S. Schnittger, W. Kern, 2015, Haematologica.

The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia

J. Cigudosa, J. Fitzgibbon, M. Calasanz, 2017, Leukemia.

Maternal uniparental disomy for chromosome 14.

E. Zackai, G. Reifenberger, T. Dierks, 1991, Journal of medical genetics.

Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.

Martin C. Müller, J. Hasford, A. Zander, 2010, Blood.

Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2012, Leukemia.

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort

T. Haferlach, W. Hofmann, C. Haferlach, 2023, Leukemia.

Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms

C. Haferlach, A. Chase, N. Cross, 2017, Leukemia.

Monitoring of minimal residual disease in acute myeloid leukemia

T. Haferlach, S. Schnittger, W. Kern, 2008, Cancer.

Mesangiocapillary glomerulonephritis.

E. Zackai, I. Harting, B. McGuinness, 1992, Journal of the American Society of Nephrology : JASN.

PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis

Y. Kamatani, S. Miyano, Y. Shiraishi, 2019, Blood.

The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age

C. Kaleta, M. Schrappe, J. Kässens, 2023, HemaSphere.

SF3B1 Mutations Have Adverse Impact On Time to Treatment Especially in Patients with 13q Deletions: A Study On 1,124 Chronic Lymphocytic Leukemia (CLL) Patients

A. Kohlmann, T. Haferlach, S. Schnittger, 2012 .

A Comprehensive Cytogenetic and Molecular Genetic Characterization of Patients with T-PLL Revealed Two Distinct Genetic Subgroups and JAK3 Mutations As an Important Prognostic Marker

T. Haferlach, S. Schnittger, W. Kern, 2014 .

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

T. Haferlach, S. Schnittger, W. Kern, 2010, Blood.

Treatment optimization by high-dose imatinib: Randomized comparison of imatinib 800 mg versus imatinib 400 mg {+/-} IFN in newly diagnosed BCR-ABL positive chronic phase (CP) CML: The German CML-study IV.

J. Hasford, A. Gratwohl, C. Haferlach, 2010 .

Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia

T. Haferlach, A. Borkhardt, S. Schnittger, 2014, Leukemia.

Identification of a MYO18A‐PDGFRB fusion gene in an eosinophilia‐associated atypical myeloproliferative neoplasm with a t(5;17)(q33‐34;q11.2)

C. Haferlach, A. Reiter, N. Cross, 2009, Genes, chromosomes & cancer.

IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status.

T. Haferlach, S. Schnittger, W. Kern, 2010, Blood.

T. Haferlach, S. Schnittger, W. Kern, 2011, Experimental Hematology.

Microarray-Genexpressionsanalysen in der Leukämiediagnostik

A. Kohlmann, T. Haferlach, S. Schnittger, 2006, Medizinische Klinik.

IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies

T. Haferlach, B. Falini, W. Kern, 2018, Leukemia.

T. Haferlach, S. Schnittger, W. Kern, 2013, Leukemia & lymphoma.

Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics

A. Kohlmann, T. Haferlach, S. Schnittger, 2011, Leukemia.

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.

A. Trumpp, H. Blum, D. Nowak, 2016, Blood.

Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2011, The Journal of molecular diagnostics : JMD.

Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies

A. Kohlmann, T. Haferlach, S. Schnittger, 2010, Annals of Hematology.

Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype

S. Ogawa, T. Haferlach, S. Schnittger, 2009, Haematologica.

[Diagnostics of acute leukemias: interaction of phenotypic and genetic methods].

T. Haferlach, S. Schnittger, W. Kern, 2012, Der Pathologe.

BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias

B. Johansson, T. Fioretos, T. Haferlach, 2008, Leukemia.

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.

Martin C. Müller, H. Einsele, J. Hasford, 2011, Blood.

Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML

T. Haferlach, S. Schnittger, W. Kern, 2010, Genes, chromosomes & cancer.

SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.

S. Ogawa, A. Kohlmann, T. Haferlach, 2010, Blood.

Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets

T. LaFramboise, T. Haferlach, J. Barnard, 2023, Leukemia.

Molecular and Cytogenetic Response After 3 Months of Imatinib Treatment Is Predictive for the Risk of Disease Progression and Death in Newly Diagnosed Chronic Myeloid Leukemia Patients – a Follow-up Analysis of the German CML Study IV

Martin C. Müller, H. Einsele, M. Pfreundschuh, 2011 .

The molecular profile of adult T‐cell acute lymphoblastic leukemia: Mutations in RUNX1 and DNMT3A are associated with poor prognosis in T‐ALL

A. Kohlmann, T. Haferlach, S. Schnittger, 2013, Genes, chromosomes & cancer.

Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype.

T. Haferlach, S. Schnittger, W. Kern, 2012, Leukemia research.

Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases

A. Kohlmann, T. Haferlach, S. Schnittger, 2014, Haematologica.

The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing

T. Haferlach, W. Kern, E. Thompson, 2023, Blood advances.

Characterization of MYD88 mutated Lymphoplasmacytic Lymphoma in Comparison to MYD88 mutated Chronic Lymphocytic Leukemia

T. Haferlach, W. Kern, C. Haferlach, 2015 .

Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis

Martin C. Müller, C. Haferlach, A. Reiter, 2010, Haematologica.

Elevated fibrinogen ratio is associated with cardiovascular diseases and acute phase reaction but not with clinical outcome

C. Haferlach, 2009 .

Identification and functional characterization of imatinib‐sensitive DTD1‐PDGFRB and CCDC88C‐PDGFRB fusion genes in eosinophilia‐associated myeloid/lymphoid neoplasms

T. Haferlach, W. Hofmann, C. Haferlach, 2014, Genes, chromosomes & cancer.

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL

C. Haferlach, M. Stelljes, W. Walter, 2023, Blood.

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma

A. Rosenwald, J. Keats, A. Krishnan, 2023, Nature Medicine.